Skip to main content

Peer Review reports

From: The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

Original Submission
5 May 2018 Submitted Original manuscript
17 Sep 2018 Author responded Author comments - Gustavo Werutsky
Resubmission - Version 2
17 Sep 2018 Submitted Manuscript version 2
30 Sep 2018 Reviewed Reviewer Report - Aurelius Omlin
5 Nov 2018 Reviewed Reviewer Report - Mark Garzotto
20 Nov 2018 Author responded Author comments - Gustavo Werutsky
Resubmission - Version 3
20 Nov 2018 Submitted Manuscript version 3
21 Dec 2018 Reviewed Reviewer Report - Aurelius Omlin
15 Apr 2019 Author responded Author comments - Gustavo Werutsky
Resubmission - Version 4
15 Apr 2019 Submitted Manuscript version 4
17 Apr 2019 Author responded Author comments - Gustavo Werutsky
Resubmission - Version 5
17 Apr 2019 Submitted Manuscript version 5
6 May 2019 Author responded Author comments - Gustavo Werutsky
Resubmission - Version 6
6 May 2019 Submitted Manuscript version 6
Publishing
14 May 2019 Editorially accepted
23 May 2019 Article published 10.1186/s12885-019-5709-y

You can find further information about peer review here.

Back to article page